Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden.
about
Attempted suicide in bipolar disorder: risk factors in a cohort of 6086 patientsCan exercise increase fitness and reduce weight in patients with schizophrenia and depression?Predictors of natural and unnatural mortality among patients with personality disorder: evidence from a large UK case registerRisk Estimates and Risk Factors Related to Psychiatric Inpatient Suicide-An Overview.Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas.Excess cause-specific mortality in out-patients with personality disorderYears of life lost due to external causes of death in the lodz province, poland.Modifiable health risk behaviours and attitudes towards behaviour change of clients attending community-based substance use treatment servicesIncreased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disordersThe Positive and Negative Experiences of Caregiving for Siblings of Young People with First Episode Psychosis.The impact of hip fracture on mortality in Estonia: a retrospective population-based cohort study.Dietary patterns are associated with obesity in Japanese patients with schizophrenia.Risks of all-cause and suicide mortality in mental disorders: a meta-review.Depression and cardiovascular disease: an update on how course of illness may influence risk.Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.Mortality among people with severe mental disorders who reach old age: a longitudinal study of a community-representative sample of 37,892 men.Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries.Sexually dimorphic, developmental, and chronobiological behavioral profiles of a mouse mania model.Mortality and life expectancy of people with alcohol use disorder in Denmark, Finland and Sweden.Protocol for CHANGE: a randomized clinical trial assessing lifestyle coaching plus care coordination versus care coordination alone versus treatment as usual to reduce risks of cardiovascular disease in adults with schizophrenia and abdominal obesitMaximal strength training as physical rehabilitation for patients with substance use disorder; a randomized controlled trial.Salivary Melatonin in Relation to Depressive Symptom Severity in Young AdultsMortality, Rehospitalisation and Violent Crime in Forensic Psychiatric Patients Discharged from Hospital: Rates and Risk Factors.Adolescents in a residential school for behavior disorders have an elevated mortality risk in young adulthood.Clinicians' adherence to clinical practice guidelines for cardiac function monitoring during antipsychotic treatment: a retrospective report on 434 patients with severe mental illness.Mortality in Schizophrenia and Other Psychoses: Data from the South Korea National Health Insurance Cohort, 2002-2013.High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia: a nationwide survey.Attitudes and Confidence in the Integration of Psychiatry ScaleAbnormal glycemic homeostasis at the onset of serious mental illnesses: A common pathwayThe CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesiImpaired Aerobic Endurance and Muscular Strength in Substance Use Disorder Patients: Implications for Health and Premature DeathMortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987-2010.Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder.Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis.All-Cause Mortality in Women With Severe Postpartum Psychiatric DisordersMortality risk in a nationwide cohort of individuals with tic disorders and with tourette syndrome.Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care.Early intervention services in psychosis: from evidence to wide implementation.
P2860
Q21132062-7383F33A-F6BC-42C0-8CC0-3FE6C6118AEAQ27023984-837A5BFD-5B8D-4DD5-8F7B-AECFC35D6F01Q28540438-B14B2C8D-D9E0-44D9-8F9D-A6AC29792402Q30235448-D8A5CFD2-2578-405D-863C-1EA245F1C7B4Q30379171-2C17276F-24DB-4AFF-BB7A-9AA959903A54Q30489975-F5CBAD2C-5E14-44F4-8655-A2078FCF8C4DQ33584138-7C0F0930-D5DC-4A51-9AEC-E12C1DBAB9BCQ33698218-E72E2827-81B3-4AC6-AB89-ADE325C223E3Q33703032-E6706C65-CE31-4302-8805-E4CE1F5DA9B9Q33715665-1E6E3C03-5EC8-45DE-874F-6AED89BD2DA9Q33768328-DCF0E1AE-9031-4177-BB41-E9CDD0089EA3Q33865512-8365752C-56EE-450F-8B90-670B9AD24DCAQ33915499-6AD20028-EF98-4905-8912-1EAC6C07C64BQ34130495-C50D1BF2-9D8D-4422-8E8F-7B18E9896E4AQ34248044-447E8D29-CE8F-4F0D-B9B1-045B4F6E93E4Q34435216-2B8D2820-DF9C-4215-B16B-0669404B02EDQ34796516-47B5B6B8-47F8-4494-9E6B-94E0CA86076BQ34964892-83206153-3B0A-4018-B030-7F0A1D13A64CQ35468653-9C2177D1-1E3A-4E71-AF2E-D772B2946612Q35700367-111A72DA-E9CA-4E50-91D5-7699B46B41D9Q35978896-23CDF148-F99B-49B4-A990-CD2807A01A23Q35978977-0B2FD950-F8E8-4ABA-B180-801E914745F3Q36022514-9899257A-EB37-40CC-9EF8-C53CA08FD3A7Q36072020-C358EB2A-8685-4AD8-80F2-558EEC49FA0DQ36328767-C1352921-A3AC-4905-B6ED-DD3BF6CEB692Q36335360-1A848003-0D54-4EAB-927E-9120DBE642A4Q36374026-DB9532AC-365D-4EBE-AD82-246DC5185D4EQ36599379-3B6503F1-2CD1-4306-BA8A-79EE47DB8DF2Q36835108-9A262F86-9BC2-440B-9E35-B4BA5EDAEECEQ37015355-28FC6A70-BE43-4364-BCC7-DAF495044435Q37026170-BDD8ECBD-3B8C-4765-B1A8-C8B776E5E97AQ37318740-BE41D661-AA03-4D55-BC5C-3FE9626CD56CQ37397705-E2673BA9-B1A9-4BFC-B97F-6A21A7584C29Q37516654-766F121A-B741-47E4-B647-022E5F9AD2BBQ37633458-86BB36C7-BD47-4143-98DA-63E4527392F0Q37635208-82AA3298-B0F6-4C15-B49D-CFA382802978Q37665999-63D93332-0A9C-4714-9AE7-6C8C7F41B2F6Q38401988-4051AE2B-5BB4-414B-9C00-80EE419EF7E6Q38469831-08F3393C-B450-44A4-B3EA-2A848CB3DECBQ38585361-06A51E91-9502-4836-9294-239430710FBD
P2860
Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Excess mortality, causes of de ...... n Denmark, Finland and Sweden.
@ast
Excess mortality, causes of de ...... n Denmark, Finland and Sweden.
@en
Excess mortality, causes of de ...... n Denmark, Finland and Sweden.
@nl
type
label
Excess mortality, causes of de ...... n Denmark, Finland and Sweden.
@ast
Excess mortality, causes of de ...... n Denmark, Finland and Sweden.
@en
Excess mortality, causes of de ...... n Denmark, Finland and Sweden.
@nl
prefLabel
Excess mortality, causes of de ...... n Denmark, Finland and Sweden.
@ast
Excess mortality, causes of de ...... n Denmark, Finland and Sweden.
@en
Excess mortality, causes of de ...... n Denmark, Finland and Sweden.
@nl
P2093
P2860
P50
P921
P1433
P1476
Excess mortality, causes of de ...... n Denmark, Finland and Sweden.
@en
P2093
Hassan Alinaghizadeh
Jonas Hällgren
Urban Osby
P2860
P304
P356
10.1371/JOURNAL.PONE.0055176
P407
P577
2013-01-25T00:00:00Z